A novel series of adenosine A2A receptor antagonists was identified by high-throughput screening of an encoded combinatorial compound collection. The initial hits were optimized for A2A binding affinity, A1 selectivity, and in vitro microsomal stability generating orally available 2-aminoimidazo [4, 5-b] pyridine-based A2A antagonist leads.